This newly launched institute will be the centre of excellence in the treatment of all cancers under a single roof.
Lenalidomide is used to treat various types of cancers.
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
Subscribe To Our Newsletter & Stay Updated
